India must use the AYUSH opportunity

AYUSH: India Must Use the AYUSH Opportunity

UPSC Study Note | GS-II & GS-III | March 2026 Editorial

1. At a Glance

• AYUSH stands for Ayurveda, Yoga & Naturopathy, Unani, Siddha, and Homoeopathy — a cluster of traditional and alternative medicine systems formalized under a dedicated Union Ministry (est. 2014). [S1]
• The Ministry's budget has nearly doubled in five years, reaching ₹4,408.93 crore in 2026-27, signalling a strategic push to mainstream traditional medicine. [S2]
• The India–EU Free Trade Agreement (FTA, January 2026) for the first time opens European markets to Indian AYUSH practitioners, marking a geopolitical and commercial inflection point. [S3]
• UPSC aspirants must understand AYUSH across at least four GS dimensions: health governance (GS-II), economic exports (GS-III), international relations (GS-II), and ethical standardisation.

2. Why in the News

• Union Budget 2026-27 (Feb 2026): FM Nirmala Sitharaman announced three new All-India Institutes of Ayurveda (AIIA) — modelled on AIIMS — and a 66.5% hike in the National AYUSH Mission (NAM) budget (₹780.96 cr → ₹1,300 cr). [S2]
• India–EU FTA concluded 27 January 2026: Provisions allow Indian AYUSH practitioners to offer services in EU member states that do not specifically regulate traditional medicine, using Indian qualifications. Indian companies can open AYUSH establishments in these countries. [S3][S4]
• WHO–Ministry of AYUSH Project Collaboration Agreement: WHO partnered with India to standardise traditional and complementary medicine systems and integrate them into national and international health frameworks. [S5]

3. Background & Evolution

• 1995: Department of Indian System of Medicine & Homoeopathy (ISM&H) created under Ministry of Health.
• 2014: Upgraded to Ministry of AYUSH — a full, standalone ministry — under the NDA government, reflecting political and policy priority.
• 2014: National AYUSH Mission (NAM) launched as a Centrally Sponsored Scheme to strengthen AYUSH services, education, and quality control at state level. [S5]
• 2016: All India Institute of Ayurveda (AIIA), New Delhi established — India's apex Ayurveda institution for tertiary care, education, and research.
• 2020-21: COVID-19 pandemic triggered massive surge in demand for AYUSH products (immunity boosters, Coronil controversy); government fast-tracked regulations.
• 2021: AYUSH Export Promotion Council operationalised; AYUSH products placed under a dedicated export category.
• 2022: First WHO Global Summit on Traditional Medicine held at Gandhinagar, Gujarat — India hosted, signalling international leadership. [S6]
• 2023: WHO–AYUSH Project Collaboration Agreement signed to standardise T&CM globally. [S5]
• 2026: Budget doubles down; India–EU FTA embeds AYUSH in a major multilateral trade framework. [S3]

4. Core Static Facts

5. Multi-Dimensional Analysis

Economic

• AYUSH sector estimated at ₹18,000+ crore domestically; global herbal medicine market projected at USD 7 trillion by 2050 (WHO estimates). [S5]
• India-EU FTA provisions allow market access for AYUSH practitioners and firms in EU without re-certification where traditional medicine is unregulated — a significant export facilitation. [S3]
• 66.5% hike in NAM funding targets modernisation of dispensaries, AYUSH clinics inside government hospitals, and upgrade of drug-testing labs — supply-side investment to reduce import dependency and scale exports. [S2]
• Three new AIIAs create high-skill employment in research, teaching, and tertiary care at par with AIIMS eco-systems.

Social / Health Equity

• NAM's mandate includes rural and tribal health coverage through AYUSH dispensaries and sub-centres — last-mile healthcare access where allopathic infrastructure is thin.
• AYUSH mainstreaming within government hospitals (not as parallel silo) addresses integration vs. replacement debate — the Budget framing explicitly positions AYUSH as complementary, not alternative.
• Gender dimension: Traditional medicine systems are disproportionately used by women (maternal, gynaecological care); women-led cottage industries (oils, formulations) also benefit from export expansion.

Geopolitical / Strategic

• India–EU FTA (January 2026): AYUSH provisions are non-tariff market access wins — practitioners can work in EU under Indian qualifications where no EU regulation exists. [S3]
• Soft-power projection: AYUSH (especially Yoga) is India's most globally visible cultural export; WHO partnership institutionalises this as a health diplomacy tool. [S5]
• Hosting the WHO Global Summit on Traditional Medicine (2022, Gandhinagar) positioned India as global norm-setter for T&CM — directly leveraged by subsequent FTA negotiations. [S6]
• China competition: China's TCM (Traditional Chinese Medicine) is the main geopolitical rival in global herbal medicine; India must accelerate clinical evidence generation to differentiate.

Scientific / Technological

• The article's core argument: AYUSH must submit to rigorous, independent, transparent scientific evaluation to credibly enter the global mainstream — peer-reviewed clinical trials, pharmacovigilance, and standardised dosimetry are prerequisites. [S7]
• Drug-testing lab upgrades (funded in Budget 2026-27) are foundational to quality assurance and regulatory equivalence — necessary for EU market access. [S2]
• Pharmacopoeia standardisation: AYUSH pharmacopoeial standards lag behind allopathic equivalents; WHO collaboration targets harmonisation. [S5]
• AYUSH Research Portal and Central Council for Research in Ayurvedic Sciences (CCRAS), Central Council for Research in Unani Medicine (CCRUM) are existing R&D bodies whose evidence base remains thin for global regulatory acceptance.

Ethical / Governance

• Credibility gap: Unverified disease claims (e.g., COVID-19 cures) damage international reputation; the article authors argue for mandatory independent evaluation before any global push.
• Regulation asymmetry: AYUSH drugs are governed under weaker evidentiary standards than allopathic drugs under the Drugs & Cosmetics Act — a gap the Drug Controller needs to close.
• Quality control: Adulteration, heavy metal contamination in some Ayurvedic preparations is a persistent scandal; lab upgrades are partly a governance response to this.
• Informed consent: Practitioners operating in EU states must work within EU consumer-protection law — ethical obligations around efficacy claims are higher than in India.

Administrative

• Centre–State split under NAM: States must create matching AYUSH infrastructure; uneven absorption capacity creates inequitable geographic outcomes.
• Integration bottleneck: Placing AYUSH clinics inside government (allopathic) hospitals requires inter-departmental coordination and potential turf conflicts with medical establishment.
• Faculty shortage: New AIIAs require trained faculty; India does not yet have a pipeline of research-grade AYUSH educators.

6. Recent Developments (Last 12–18 Months)

• January 2026: India–EU FTA concluded — first trade deal to explicitly include AYUSH practitioner mobility and firm establishment rights in EU. [S3]
• Feb 2026 (Budget 2026-27): AYUSH Ministry allocation raised to ₹4,408.93 crore (~20% over RE 2025-26); NAM gets 66.5% hike; 3 new AIIAs announced. [S2]
• 2025-26 (Budget 2025-26): Ministry allocation raised 14% to ₹3,992.90 crore from ₹3,497.64 crore (RE 2024-25). [S2]
• 2023: WHO–Ministry of AYUSH Project Collaboration Agreement signed — scope: quality, safety, standardisation, global dissemination of T&CM. [S5]
• March 2026: Op-ed in The Hindu (Chopra & Siddiqui, Krea University) argues for rigorous scientific evaluation as the necessary condition for AYUSH's global credibility — highlights gap between political ambition and evidentiary standards. [S7]

7. Prelims Hooks

1. Ministry of AYUSH was created as a standalone ministry in November 2014 (previously a department under Ministry of Health).
2. National AYUSH Mission (NAM) is a Centrally Sponsored Scheme launched in 2014.
3. AYUSH Ministry budget in 2026-27: ₹4,408.93 crore — a ~20% increase over revised estimates of 2025-26. [S2]
4. National AYUSH Mission allocation in 2026-27: ₹1,300 crore — a 66.5% jump over 2025-26 allocation of ₹780.96 crore. [S2]
5. Budget 2026-27 announced 3 new All-India Institutes of Ayurveda — modelled on AIIMS for teaching, treatment, and research.
6. India–EU FTA was concluded on 27 January 2026 — includes provisions for AYUSH practitioner mobility in EU member states. [S3]
7. EU countries where Ayurvedic treatment is currently regulated: Romania, Hungary, Latvia, Serbia, and Slovenia. [S4]
8. The first WHO Global Summit on Traditional Medicine was held at Gandhinagar, Gujarat (2022) — hosted by India. [S6]
9. WHO–Ministry of AYUSH Project Collaboration Agreement: signed to standardise T&CM and integrate into national health systems globally. [S5]
10. All India Institute of Ayurveda (AIIA) — India's apex Ayurveda institution — is located in New Delhi (established 2016).
11. The AYUSH Export Promotion Council was operationalised to promote exports of AYUSH products under a dedicated category.
12. AYUSH drugs are regulated under the Drugs and Cosmetics Act, 1940 — not under a separate AYUSH-specific statute.
13. Central Council for Research in Ayurvedic Sciences (CCRAS) is the apex body for Ayurveda research under Ministry of AYUSH.
14. India's AYUSH sector is estimated at over ₹18,000 crore domestically; the global herbal medicine market is projected at USD 7 trillion by 2050 per WHO estimates.

8. Mains Relevance

GS Papers: - GS-II: Government policies and interventions for development in various sectors; issues relating to health; bilateral/multilateral agreements. - GS-III: Indian economy; export promotion; science & technology in India.

Specific Syllabus Headings: - GS-II: Issues relating to development and management of social sector — Health; India and its neighbourhood / bilateral agreements. - GS-III: Infrastructure — Health; Science & Technology; Growth and development.

Plausible Mains Questions: 1. "The Union Budget 2026-27 has made significant investments in the AYUSH sector. Critically evaluate the opportunities and challenges of positioning India's traditional medicine systems in the global mainstream." (GS-II/III, 15 marks) 2. "India's traditional medicine diplomacy has found expression in the India-EU FTA and WHO partnership. Assess the geopolitical and economic significance of AYUSH's internationalisation." (GS-II, 10 marks) 3. "Mainstreaming AYUSH into India's public health system requires both institutional investment and scientific rigour. Discuss the administrative and ethical challenges involved." (GS-II + GS-IV, 15 marks)

9. Related Topics to Study Next

10. Common Errors / Trap Areas

1. Wrong ministry year: AYUSH became a standalone ministry in 2014, not 2015 or 2016 — aspirants confuse this with AIIA establishment (2016).
2. NAM vs. PM-JAY confusion: National AYUSH Mission (NAM) and Ayushman Bharat are separate schemes under different ministries; NAM is under Ministry of AYUSH, PM-JAY under Ministry of Health & Family Welfare.
3. Budget figure confusion: Three figures exist — Ministry total (₹4,408 cr), NAM allocation (₹1,300 cr), and the percentage hike (66.5% for NAM, ~20% for overall Ministry); do not conflate them.
4. "5 EU countries regulate Ayurveda": Romania, Hungary, Latvia, Serbia, Slovenia — note that Serbia is NOT an EU member (EU candidate); aspirants may miscategorise it as a full EU state.
5. AYUSH as "alternative" not "complementary": The policy framing has explicitly shifted — Budget 2026-27 positions AYUSH as complementary and integrative, not a replacement for allopathic care; answers treating it as purely "alternative medicine" will lose marks.
6. CCRAS vs. ICMR: Central Council for Research in Ayurvedic Sciences (CCRAS) is the AYUSH research body — do not substitute with ICMR, which handles biomedical/allopathic research.

11. Sources

• [S1] Ministry of AYUSH — Official Website, About AYUSH — https://main.mohfw.gov.in (tier: 1)
• [S2] Notes on Demands for Grants 2026-27, Ministry of AYUSH (No. 4) — https://www.indiabudget.gov.in/doc/eb/sbe4.pdf — (tier: 1)
• [S3] India–EU Free Trade Agreement Concluded — PIB Press Release — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2219065 — (tier: 1)
• [S4] India's Achievements in Free Trade Agreements 2025-26 — PIB — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2236134 — (tier: 1)
• [S5] WHO and Ministry of AYUSH signed Traditional and Complementary Medicine Project Collaboration Agreement — PIB — https://www.pib.gov.in/PressReleasePage.aspx?PRID=1977854 — (tier: 1)
• [S6] First-ever WHO Global Summit on Traditional Medicine, Gandhinagar — PIB — https://pib.gov.in/PressReleasePage.aspx?PRID=1949585 — (tier: 1)
• [S7] "India must use the AYUSH opportunity" — Suchika Chopra & Sabah Siddiqui, Krea University — The Hindu, 23 March 2026 — https://www.thehindu.com/todays-paper/2026-03-23/th_international/articleGS2FOIKF5-13954929.ece — (tier: 4)

Note on Serbia (S4): Search snippets listed Serbia among countries where Ayurveda is regulated alongside EU members Romania, Hungary, Latvia, and Slovenia. Serbia is an EU candidate state, not a full member — verify before using in answers about intra-EU regulation.